MarketCap
Facebook
X
Telegram
Vertex Pharmaceuticals Incorporated Income Statement 2025-2011 | VRTX
Brief overview of revenue and earnings at Vertex Pharmaceuticals Incorporated
This overview is based on financial performance over the past five years. Revenue at Vertex Pharmaceuticals Incorporated moved from 6.2 billion dollars in 2020 to 12 billion dollars in 2025. Across the full period, sales moved by +93.4%; the average annual rate was 14.1%. The trajectory reflects meaningful expansion of the business.
Gross profit was $5.5 billion at the start and $10.3 billion at the end of the period (+89.2%). Cost of revenue developed less favorably than sales and pressured gross profitability. At the margin level, the figure shifted from 88.1% to 86.2%. Gross profitability remained broadly stable.
EBITDA changed from 3 billion dollars to 4.4 billion dollars (+47.8%). Operating performance weakened relative to revenue. EBITDA margin moved from 47.8% to 36.5%. A lower EBITDA share weakens the quality of the result.
Net profit was 2.7 billion dollars at the start and 4 billion dollars at the end. The latest figure was the best within the selected horizon.
Over the period, capitalization shifted from $61.4 billion to $125 billion (+104%). The share-price trend was broadly consistent with improving results.
Overall conclusion
The five-year picture requires weighing both strengths and weaknesses. The strongest signals are revenue expansion and net-income growth. The main areas of concern are a lower gross margin and pressure on operating profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
125 B | 120 B | 110 B | 76.1 B | 56.6 B | 61.4 B | 59.1 B | 47.6 B | 41.4 B | 20.6 B | 21.9 B | 25.9 B | 18.5 B | 9.46 B | 7.12 B |
Shares |
256 M | 258 M | 258 M | 256 M | 258 M | 260 M | 257 M | 254 M | 249 M | 245 M | 241 M | 235 M | 225 M | 212 M | 205 M |
Historical Prices |
490 | 463 | 426 | 297 | 220 | 236 | 219 | 166 | 150 | 73.7 | 126 | 119 | 74.3 | 41.9 | 33.2 |
Net Income |
3.95 B | -536 M | 3.62 B | 3.32 B | 2.34 B | 2.71 B | 1.18 B | 2.1 B | 263 M | -112 M | -556 M | -739 M | -445 M | -107 M | 29.6 M |
Revenue |
12 B | 11 B | 9.87 B | 8.93 B | 7.57 B | 6.21 B | 4.16 B | 3.05 B | 2.49 B | 1.7 B | 1.03 B | 580 M | 1.21 B | 1.53 B | 1.41 B |
Cost of Revenue |
1.65 B | 1.53 B | 1.26 B | 1.08 B | 904 M | 736 M | 548 M | 410 M | 275 M | 210 M | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 3.62 B | 2.64 B | 2.21 B | 1.49 B | 908 M | 519 M | 1.08 B | 1.25 B | 1.33 B |
Operating Income |
4.17 B | -233 M | 3.83 B | 4.31 B | 2.78 B | 2.86 B | 1.2 B | 635 M | 123 M | 9.94 M | -467 M | -692 M | -610 M | 46.7 M | 114 M |
Interest Expense |
-7.7 M | -86.1 M | -22.8 M | -165 M | 4.9 M | 297 M | 58.5 M | 72.5 M | 69.3 M | 4.13 M | -6.72 M | 30.4 M | 6.89 M | 16.7 M | 38.5 M |
EBITDA |
4.38 B | -25.7 M | 4.01 B | 4.46 B | 2.91 B | 2.97 B | 1.31 B | 736 M | 454 M | 72.6 M | -402 M | -578 M | -151 M | 42.4 M | 257 M |
Operating Expenses |
- | - | - | - | - | - | 2.41 B | 1.97 B | 1.82 B | 1.48 B | 1.37 B | 1.16 B | 1.28 B | 1.24 B | 1.11 B |
General and Administrative Expenses |
1.75 B | 1.46 B | 1.14 B | 945 M | 840 M | 770 M | 658 M | 558 M | 496 M | 433 M | 377 M | 305 M | 362 M | 437 M | 401 M |
All numbers in USD currency
Quarterly Income Statement Vertex Pharmaceuticals Incorporated
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
254 M | 254 M | 256 M | 257 M | 257 M | 257 M | 258 M | 258 M | 258 M | 258 M | 258 M | 258 M | 257 M | 257 M | 256 M | 256 M | 255 M | 254 M | 258 M | 259 M | 259 M | 260 M | 260 M | 260 M | 260 M | 258 M | 257 M | 256 M | 256 M | 255 M | 255 M | 254 M | 253 M | 252 M | 250 M | 248 M | 246 M | 245 M | 245 M | 244 M | 244 M | 243 M | 242 M | 241 M | 239 M | 238 M | 236 M | 234 M | 233 M | 231 M | 231 M | 222 M | 215 M | 215 M | 214 M | 211 M | 208 M | 207 M | 206 M | 204 M | 202 M |
Net Income |
1.03 B | - | 1.08 B | 1.03 B | 646 M | - | 1.05 B | -3.59 B | 1.1 B | - | 1.04 B | 916 M | 700 M | - | 930 M | 810 M | 762 M | - | 852 M | 66.9 M | 653 M | 604 M | 667 M | 837 M | 603 M | 583 M | 57.5 M | 267 M | 269 M | 1.55 B | 129 M | 207 M | 210 M | 101 M | -103 M | 18 M | 248 M | 32.9 M | -38.8 M | -64.5 M | -41.6 M | -73.7 M | -95.1 M | -189 M | -199 M | -177 M | -170 M | -159 M | -232 M | 44.3 M | -124 M | -57.2 M | -308 M | -76.1 M | -57.5 M | -64.9 M | 91.6 M | 159 M | 221 M | -174 M | -176 M |
Revenue |
2.99 B | - | 3.08 B | 2.96 B | 2.77 B | - | 2.77 B | 2.65 B | 2.69 B | - | 2.48 B | 2.49 B | 2.37 B | - | 2.33 B | 2.2 B | 2.1 B | - | 1.98 B | 1.79 B | 1.72 B | 1.63 B | 1.54 B | 1.52 B | 1.52 B | 1.41 B | 950 M | 941 M | 858 M | 870 M | 785 M | 752 M | 641 M | 652 M | 578 M | 544 M | 715 M | 459 M | 414 M | 432 M | 398 M | 418 M | 310 M | 166 M | 139 M | 145 M | 179 M | 138 M | 118 M | 351 M | 222 M | 311 M | 328 M | 334 M | 336 M | 418 M | 439 M | 563 M | 659 M | 114 M | 73.7 M |
Cost of Revenue |
393 M | - | 415 M | 408 M | 363 M | - | 393 M | 372 M | 343 M | - | 319 M | 309 M | 267 M | - | 289 M | 262 M | 246 M | - | 236 M | 228 M | 192 M | 203 M | 186 M | 185 M | 162 M | 185 M | 132 M | 136 M | 95.1 M | 122 M | 111 M | 104 M | 71.6 M | 84.1 M | 72.9 M | 71.2 M | 47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
1.14 B | - | 1.19 B | 1.15 B | 630 M | - | 1.12 B | -3.51 B | 1.14 B | - | 1.04 B | 1.03 B | 779 M | - | 1.13 B | 1.11 B | 1.04 B | - | 1.05 B | -38 M | 888 M | 746 M | 672 M | 718 M | 720 M | 551 M | 99.3 M | 270 M | 277 M | 128 M | 206 M | 173 M | 129 M | 126 M | -326 M | 52.7 M | 271 M | 39.6 M | -18.7 M | 3.35 M | -14.3 M | -53.7 M | -70 M | -171 M | -172 M | -154 M | -142 M | -181 M | -216 M | -10.3 M | -124 M | -47 M | -429 M | -77.5 M | -1.07 M | -10.8 M | 91.6 M | 224 M | 216 M | -166 M | -160 M |
Interest Expense |
- | - | -9.8 M | 13.2 M | -17.6 M | - | -16.9 M | -23.1 M | -31.2 M | - | -15.9 M | 1.6 M | 1.3 M | - | 17.2 M | -78.1 M | -72.8 M | - | 42.4 M | 8.05 M | -52.7 M | 16.3 M | 13.9 M | 13.9 M | 14.1 M | 14.2 M | 14.5 M | 14.8 M | 14.9 M | 18.7 M | 18.7 M | 18.2 M | 16.9 M | -748 K | -77.6 M | -2.54 M | -544 K | 1.1 M | -167 K | -1.22 M | 4.41 M | -1.69 M | -1.33 M | 1.41 M | -5.11 M | -3.79 M | -3.99 M | 37.7 M | 451 K | 3.34 M | 4.76 M | -34 K | -1.18 M | 33 K | -13 K | -179 K | -150 K | 12.4 M | 7.06 M | 6.96 M | 12 M |
EBITDA |
1.19 B | - | 1.24 B | 1.2 B | 678 M | - | 1.17 B | -3.46 B | 1.19 B | - | - | - | 818 M | - | 1.24 B | 1.11 B | 1.08 B | - | 1.15 B | -38 M | 917 M | 746 M | 752 M | 772 M | 747 M | 551 M | 180 M | 325 M | 304 M | 128 M | 259 M | 207 M | 145 M | 126 M | -281 M | 82.4 M | 286 M | 39.6 M | 27.2 M | 34.7 M | 2.08 M | -53.7 M | -23.4 M | -141 M | -156 M | -154 M | -95.3 M | -151 M | -200 M | -10.3 M | -92.8 M | -25.8 M | -418 M | -77.5 M | 24.7 M | 6.46 M | 100 M | 224 M | 241 M | -148 M | -151 M |
General and Administrative Expenses |
494 M | - | 445 M | 425 M | 396 M | - | 372 M | 372 M | 343 M | - | 264 M | 263 M | 241 M | - | 247 M | 215 M | 215 M | - | 198 M | 195 M | 192 M | 212 M | 185 M | 192 M | 182 M | 195 M | 160 M | 157 M | 147 M | 153 M | 137 M | 137 M | 130 M | 135 M | 121 M | 127 M | 113 M | 110 M | 106 M | 112 M | 105 M | 96.5 M | 99.8 M | 94.4 M | 85.9 M | 78.5 M | 75.2 M | 77.4 M | 74.2 M | 73.1 M | 86.4 M | 105 M | 91.6 M | 110 M | 97.7 M | 118 M | 111 M | 122 M | 111 M | 96.7 M | 71.5 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Vertex Pharmaceuticals Incorporated (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
